Zydus said the vaccine, which is a three-course regimen, showed safety and efficacy in a late-stage trial with more than 28,000 volunteers across the country, including about 1,000 subjects in the 12-18-year age group.Latest News of India, Sports, Tech, Technology 2021 from Top India News- News18.com for more info CLICK HERE
0 Comments